Impact of medical therapy for sympthomatic benign prostatic hyperplasia on transurethral resection of the prostate

Aleksandar Argirovic ,
Aleksandar Argirovic
Djordje Argirovic
Djordje Argirovic

Published: 01.12.2011.

Biochemistry

Volume 28, Issue 4 (2012)

pp. 733-740;

https://doi.org/10.5937/matmed1204733a

Abstract

The aim of this study is to examine how the introduction of medical therapy for symptomatic benign prostatic hyperplasia (BPH) might have changed the indications, patient characteristics and outcome in men undergoing transurethral resection of the prostate (TURP) over two decades (1991.- 2011.). All patients who underwent TURP for symptomatic BPH at our institutions in 1991. (before the introduction of medical therapy for BPH), 2001. (when medical therapy was becoming an important therapy for BPH) and 2011. (when medical therapy was the first line therapy for BPH), were reviewed. We assessed the total number of TURPs, indications for surgery, patient age, health status, weight of resected tissue, and pre and post-operative events/ complications. Our institutions provided primary urological care for 989, 1815 and 2162 men > 50 years of age in 1991., 2001. and 2011., respectively. There was a 60% decrease of TURPs from 1991. to 2011. with a slight increase in number in 2001. Failure of medical therapy was not an indication in 37% and 88% of patients in 2001. and 2011., respectively. There was a substantial rise in the percentage of men at risk presenting with acute or chronic retention (AUR and CUR) at the time of their TURPs ( from 23% in 1991. to 55% in 2001. and from 14% in 1991. to 38% in 2011. for AUR and CUR, respectively) (P<0.05). There was also rise in the percentage of patients presenting with preoperative hydronephrosis (2% in 1991., 13% in 2001. and 6% in 2011.) (P<0.05) and gradual decrease of UTI before TURP overtime (14%, 10% and 12%, respectively).The mean operative time was lower in 2011., compared with either of the two previous cohorts (P<0.05), postoperative stays decreased (from 4.1 days in 1991. to 2.7 days in 2001. and 2.1 days in 2011.)(P<0.05), but the number of patients discharged with catheter increase over two decades (from 3.5% in 1991 to 4.8% in 2001., and to 8.8% in 2011.)(P<0.05). The postoperative complications of our three cohorts differed significantly (14% in 1991., 6.4% in 2001. and 20.6% in 2011.)(P<0.05). The increasing use of medical therapy as a first line treatment for BPH has resulted in a dramatic decrease in TURPs which, in turn, has been associated with an apparent increase in risk of poor pre- and postoperative outcomes seems to be related to earlier catheter removal and hospital discharge, although a causal relationship cannot be established. The present study covering the last two decades would suggest that we are not delaying surgery for patients who will eventually require it. We are now selecting the appropriate patients for TURP, rather than using TURP as our only means of BPH therapy as we did two decades ago.

Keywords

References

1.
Girman C, Jacobsen S, Tsukamoto T. Health-related quality of life associated with lower urinary tract symptoms in four countries. Urology. 1998;428–36.
2.
Flaniger R, Reda D, Wasson J, Anderson R, Abdellatif M, Bruskowitz R. 5-Year outcome of surgical resection and watchful waiting for men with moderately symptomatic benign prostatic hyperplasia: a Department of Veterans Affairs cooperative study. J Urol. 1998;12–7.
3.
Sarma A, Jackobsen D, Mcgree M, Roberts R, Lieber M, Jacobsen S. A population based study of incidence and treatment of benign prostatic hyperplasia among residents of Olmsted Country, Minesota: 1987 to 1997. J Urol. 2005;2048–53.
4.
Mcconnell J, Bruskewitz R, Walsh P. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Eng J Med. 1998;557–63.
5.
Nickel J, Sander S, Moon T. A meta-analysis of the vascular-related safety profile and efficacy of alpha-adrenergic blockers for symptoms related to Benign Prostatic Hyperplasia. Int J Clin Pract. 2008;1547–59.
6.
Mcconnell J, Roehborn C, Bautista O. The long-term efficacy of doxazosin, finasteride, and combination therapy in the clinical progression of benign prostatic hyperplasia. N Eng J Med. 2003;2378–98.
7.
Roehborn C, Siami P, Barkin J. The effect of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4 year results from CombAT study. Eur Urol. 2010;123–31.
8.
Reich O, Gratzke C, Backmann A. Morbidity, mortality and early outcome of transurethral resection of the prostate: a prospective multicenter evaluation of 10.654 patients. J Urol. 2008;246–9.
9.
Borth C, Beiko D, Nickel J. Impact of medical therapy on transurethral resection of the prostate: a decade of change. Urology. 2001;1082–5.
10.
Dj A, Argirović A. Impact of preoperative administration of finasteride on perioperative bleeding during transurethral vapor resection of the prostate. Materia Medica. 2011;303–9.
11.
E-Mail.

Citation

Copyright

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 

Article metrics

Google scholar: See link

The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Most read articles

Partners